Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Fungal Phylum Microsporidia

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.

Pulmonology·2026

Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026

Same author

Nuclear protein 1 is a cell death regulator in primary human airway epithelial cells and reduced in idiopathic pulmonary fibrosis.

Scientific reports·2026

Same author

The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis.

Science advances·2026

Same author

Clonal Hematopoiesis Instructs Maladaptive Tissue Repair to Promote Fibrosis.

bioRxiv : the preprint server for biology·2026

Same author

Pulmonary sarcoïdosis presenting as acute hypoxemic respiratory failure.

Respiratory medicine and research·2026

Search research articles

Related Experiment Video

Updated: May 7, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Sarcoidosis.

Dominique Valeyre¹, Antje Prasse², Hilario Nunes¹

¹Department of Pneumology, Assistance Publique Hôpitaux de Paris, Avicenne University Hospital, Bobigny, France; University Paris 13, Sorbonne Paris Cité, Bobigny, France.

Lancet (London, England)

|October 5, 2013

Summary

This summary is machine-generated.

Sarcoidosis is a systemic inflammatory disease causing granulomas. Recent advances improve diagnosis and management of symptoms, but finding the cause and effective treatments remain key challenges.

Related Experiment Videos

Last Updated: May 7, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

Immunology
Pulmonology
Systemic Diseases

Background:

Sarcoidosis is a systemic disease of unknown etiology characterized by granuloma formation.
Genetic susceptibility and exposure to unidentified antigens are implicated.
It primarily affects the lungs and lymphatic system.

Purpose of the Study:

To summarize recent advancements in the diagnosis and management of sarcoidosis.
To highlight improvements in recognizing and addressing key patient symptoms and quality of life.
To outline future research directions for sarcoidosis.

Main Methods:

Review of current literature and clinical practice guidelines.
Analysis of new diagnostic indications, including endobronchial ultrasound and PET scans.
Focus on improved recognition of disabling symptoms and health status changes.

Main Results:

Enhanced specificity for endobronchial ultrasound in diagnosis.
Improved PET scan utility for assessing inflammatory activity.
Better recognition of persistent disabling symptoms like fatigue and cognitive dysfunction.

Conclusions:

Sarcoidosis diagnosis and symptom management have seen significant improvements.
Pulmonary fibrosis contributes to increased mortality.
Future research priorities include identifying the cause, biomarkers, and novel treatments for refractory cases.